Detalhe da pesquisa
1.
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Acta Pharmacol Sin
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438582
2.
Electrotaxis of alveolar epithelial cells in direct-current electric fields.
Chin J Traumatol
; 26(3): 155-161, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019724
3.
Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.
Clin Respir J
; 12(12): 2642-2652, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307719
4.
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.
Biologics
; 12: 75-86, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30154647
5.
Fabrication and characterization of stable ultrathin film micropatterns containing DNA and photosensitive polymer diazoresin.
Anal Bioanal Chem
; 384(2): 385-90, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16362289